STUDY OF RAPITALAM INFLUENCE ON OXOTREMORINE-INDUCED TREMOR

Parkinson’s disease is the second most common (after Alzheimer’s) neurodegenerative disease. All over the world, there is a search for new drugs aimed at the treatment of Parkinson’s disease. Till up to the present, there is no “ideal” medicine that can completely cure this disease and has minimal adverse side effects. Belgorod research institute of pharmacology of living systems is studying Rapitalam, a new drug for the treatment of tremulous Parkinson’s disease. This is an agonist of the mGluR4 group of metabotropic receptors.The aim of the article is to study Rapitalam influence on the oxotremorine-induced tremor in rats.Methods. The study comprised 60 rats (6 groups of 10 males), which were administered intragastrically with the studied substances for 10 days. All the animal groups except Control group 1, were administered with Rapitalam and the reference drug Levodopa. 30 minutes after Rapitalam and Levodopa, they were administered abdominally with the solution of Oxotremorine at the dose of 1.5 mg/kg. The animals of Control group 1, instead of Oxotremorine, were similarly administered with a solvent of 0.9% sodium chloride in the equivalent volume.Results. In comparison with the reference group, Rapitalam at the dose of 3 mg/kg significantly reduced the severity of tremor 50 min. after its administration. The same effect took place 30 min after the administration of Oxotremorine at the dose of 10 mg/kg. At the dose of 3 and 10 mg/kg, Rapitalam also decreased the number of rats in the group (in %) with the signs of tremor 60 min. and 50 min. after the administration of Oxotremorine, respectively.Conclusion. The study revealed that Rapitalam has a pronounced anti-tremor effect. Its administration at the studied doses reduced the symptoms of Oxotremorine-induced tremor in rats.

mGluR4, Parkinson’s Disease, mGluR4, Rapitalam, Oxotremorine-induced tremor, Levodopa